Loading...
primary Phase 3 results from the epcore FL-1 trial of epcoritamab with rituximab and lenalidomide (R2) versus R2 for relapsed or refractory follicular lymphoma
Falchi, L. Nijland, M. Huang, H. Q. Linton, K. Seymour, J. Tao, R. Kwiatek, M. Costa, A. Vassilakopoulos, T. Greil, R.
Falchi, L.
Nijland, M.
Huang, H. Q.
Linton, K.
Seymour, J.
Tao, R.
Kwiatek, M.
Costa, A.
Vassilakopoulos, T.
Greil, R.
Abstract
Authors
Falchi, L.
Nijland, M.
Huang, H. Q.
Linton, K.
Seymour, J.
Tao, R.
Kwiatek, M.
Costa, A.
Vassilakopoulos, T.
Greil, R.
Ubieto, A. J.
Gangatharan, S.
Benjamini, O.
Thieblemont, C.
Tucci, A.
Elinder-Camburn, A.
Illes, A.
Novak, J.
Pavlovsky, M.
McDonald, A.
Yoon, D. H.
Mishima, Y.
Sunkersett, G.
Mei, J.
Mukherjee, N.
Zhu, F.
Favaro, E.
Morschhauser, F.
Nijland, M.
Huang, H. Q.
Linton, K.
Seymour, J.
Tao, R.
Kwiatek, M.
Costa, A.
Vassilakopoulos, T.
Greil, R.
Ubieto, A. J.
Gangatharan, S.
Benjamini, O.
Thieblemont, C.
Tucci, A.
Elinder-Camburn, A.
Illes, A.
Novak, J.
Pavlovsky, M.
McDonald, A.
Yoon, D. H.
Mishima, Y.
Sunkersett, G.
Mei, J.
Mukherjee, N.
Zhu, F.
Favaro, E.
Morschhauser, F.
Description
Date
2025
Publisher
Collections
Files
Loading...
Found from Unpaywall
Adobe PDF, 176.78 KB
Keywords
Type
Article
Citation
Falchi L, Nijland M, Huang HQ, Linton K, Seymour J, Tao R, et al. primary Phase 3 results from the epcore FL-1 trial of epcoritamab with rituximab and lenalidomide (R2) versus R2 for relapsed or refractory follicular lymphoma. Blood. 2025 NOV 3;146:466-7.